BioDelivery Sciences International, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioDelivery Sciences International, Inc.
The numbers may be down, but Europeans will in future be able to gain access to a number of highly innovative medicines, including several products for hard-to-treat cancers, a gene therapy for severe and moderately severe hemophilia B, and two vaccines against disease caused by respiratory syncytial virus.
Private Company Financings: Year-end data from Pitchbook/NVCA, like recent Evaluate numbers, show venture fundraising slid from the third to fourth quarters. However, Taiho increased its VC fund by $100m, Ji Xing closed a $162m series D round and MAPS raised more than $100m.
The private US/Canadian firm is taking a singular approach to T-cell therapy to tackle both solid and liquid tumors and hopes to have early data to back up its novel technology this year. An IPO could follow.
The higher dose of Amgen's Lumakras combined with Vectibix has demonstrated significant superiority in progression-free survival over investigator's choice of therapy in KRAS G12C-mutated metastatic colorectal cancer but the discussant at the combo's ESMO presentation wants to see overall survival data before getting too excited.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Arius Pharmaceuticals
- Arius Two Inc
- Bioral Nutrient Delivery LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.